 Shares of Second Sight Medical Products Inc. tumbled 25 to pace all premarket decliners on Wednesday, after the implantable visual prosthetics company announced a large private placement of common stock. The share sale comes after the stock skyrocketed more than 6-fold month to date through Tuesday, after the companys Argus 2s Retinal Prosthesis System was approved by the Food and Drug Administration. 